Pembrolizumab,eftilagimod
Merck,novartis
['head and neck', 'immutep', '$immp']
immutep reports final positive data in 2nd line head and neck squamous cell carcinoma at asco 2023 annual meeting - health stocks hub $immp 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2